STOCK TITAN

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
covid-19

CSL and Arcturus Therapeutics announced results from a head-to-head study showing their self-amplifying mRNA (sa-mRNA) COVID-19 vaccine ARCT-154 maintained superior immunogenicity compared to Comirnaty® for up to one year. The study, presented at the OPTIONS XII conference, demonstrated:

1. Higher antibody levels against multiple SARS-CoV-2 strains, including Wuhan-Hu-1 and Omicron variants.

2. Effectiveness at one-sixth the dose of Comirnaty® (5 μg vs 30 μg).

3. Superior durability of immune response in both younger and older adults.

Additionally, their bivalent vaccine ARCT-2301 showed superior immunogenicity over Comirnaty® bivalent vaccine up to six months post-vaccination. The sa-mRNA platform vaccine targeting the JN.1 variant is now approved in Japan under the name KOSTAIVE®.

CSL e Arcturus Therapeutics hanno annunciato i risultati di uno studio comparativo che dimostra come il loro vaccino COVID-19 sa-mRNA (mRNA auto-amplificante) ARCT-154 abbia mantenuto un'immunogenicità superiore rispetto a Comirnaty® fino a un anno. Lo studio, presentato alla conferenza OPTIONS XII, ha dimostrato:

1. Livelli anticorpali più elevati contro diversi ceppi di SARS-CoV-2, inclusi i varianti Wuhan-Hu-1 e Omicron.

2. Efficienza a un sesto della dose di Comirnaty® (5 μg vs 30 μg).

3. Durabilità superiore della risposta immunitaria sia negli adulti più giovani che in quelli più anziani.

Inoltre, il loro vaccino bivalente ARCT-2301 ha mostrato una superiorità immunogenica rispetto al vaccino bivalente Comirnaty® fino a sei mesi dopo la vaccinazione. Il vaccino basato sulla piattaforma sa-mRNA che colpisce la variante JN.1 è ora approvato in Giappone con il nome KOSTAIVE®.

CSL y Arcturus Therapeutics anunciaron los resultados de un estudio comparativo que muestra que su vacuna COVID-19 sa-mRNA (mRNA autoamplificante) ARCT-154 mantuvo una inmunogenicidad superior en comparación con Comirnaty® durante hasta un año. El estudio, presentado en la conferencia OPTIONS XII, demostró:

1. Niveles de anticuerpos más altos contra múltiples cepas de SARS-CoV-2, incluidas las variantes Wuhan-Hu-1 y Omicron.

2. Eficacia a una sexta parte de la dosis de Comirnaty® (5 μg frente a 30 μg).

3. Durabilidad superior de la respuesta inmune tanto en adultos jóvenes como mayores.

Además, su vacuna bivalente ARCT-2301 mostró una inmunogenicidad superior en comparación con la vacuna bivalente Comirnaty® hasta seis meses después de la vacunación. La vacuna de la plataforma sa-mRNA que se dirige a la variante JN.1 ahora está aprobada en Japón bajo el nombre KOSTAIVE®.

CSL과 아크투루스 테라퓨틱스는 그들의 자가 증폭 mRNA (sa-mRNA) COVID-19 백신 ARCT-154가 Comirnaty®에 비해 최대 1년 동안 우수한 면역원성을 유지했다는 연구 결과를 발표했다. OPTIONS XII 회의에서 발표된 이 연구는 다음을 보여주었다:

1. 여러 SARS-CoV-2 변종에 대한 항체 수준이 더 높음, 포함하여 우한-Hu-1 및 오미크론 변종.

2. Comirnaty®의 6분의 1 용량에서의 효과 (5 μg 대 30 μg).

3. 젊은 성인과 노인 모두에서 면역 반응의 지속력 우수.

또한, 그들의 바이발렌트 백신 ARCT-2301은 예방접종 후 6개월까지 Comirnaty® 바이발렌트 백신에 비해 우수한 면역원성을 보였다. JN.1 변종을 겨냥하는 sa-mRNA 플랫폼 백신은 현재 일본에서 승인되었다는 이름 KOSTAIVE®로.

CSL et Arcturus Therapeutics ont annoncé les résultats d'une étude comparative montrant que leur vaccin COVID-19 sa-mRNA (mRNA auto-amplificateur) ARCT-154 a maintenu une immunogénicité supérieure par rapport à Comirnaty® pendant jusqu'à un an. L'étude, présentée à la conférence OPTIONS XII, a démontré :

1. Niveaux d'anticorps plus élevés contre plusieurs souches de SARS-CoV-2, y compris les variantes Wuhan-Hu-1 et Omicron.

2. Efficacité à un sixième de la dose de Comirnaty® (5 μg contre 30 μg).

3. Durabilité supérieure de la réponse immunitaire chez les jeunes et les adultes âgés.

De plus, leur vaccin bivalent ARCT-2301 a montré une immunogénicité supérieure par rapport au vaccin bivalent Comirnaty® jusqu'à six mois après la vaccination. Le vaccin de la plateforme sa-mRNA ciblant la variante JN.1 est maintenant approuvé au Japon sous le nom de KOSTAIVE®.

CSL und Arcturus Therapeutics haben die Ergebnisse einer Vergleichsstudie angekündigt, die zeigt, dass ihr selbstverstärkendes mRNA (sa-mRNA) COVID-19 Impfstoff ARCT-154 eine überlegene Immunogenität im Vergleich zu Comirnaty® über einen Zeitraum von bis zu einem Jahr aufrechterhielt. Die Studie, die auf der OPTIONS XII Konferenz präsentiert wurde, zeigte:

1. Höhere Antikörperwerte gegen mehrere SARS-CoV-2-Stämme, einschließlich der Wuhan-Hu-1 und Omikron Varianten.

2. Wirksamkeit bei einem Sechstel der Dosis von Comirnaty® (5 μg vs 30 μg).

3. Überlegene Haltbarkeit der Immunantwort sowohl bei jüngeren als auch bei älteren Erwachsenen.

Darüber hinaus zeigte ihr bivalenter Impfstoff ARCT-2301 eine überlegene Immunogenität im Vergleich zum bivalenten Impfstoff von Comirnaty® bis zu sechs Monate nach der Impfung. Der sa-mRNA-Plattformimpfstoff, der auf die JN.1-Variante abzielt, ist jetzt in Japan genehmigt unter dem Namen KOSTAIVE®.

Positive
  • ARCT-154 demonstrated superior immunogenicity compared to Comirnaty® for up to one year
  • ARCT-154 effective at one-sixth the dose of Comirnaty® (5 μg vs 30 μg)
  • ARCT-2301 showed superior immunogenicity over Comirnaty® bivalent vaccine up to six months post-vaccination
  • Sa-mRNA platform vaccine KOSTAIVE® approved in Japan for adults 18 years and older
Negative
  • None.

Insights

This study presents significant findings in COVID-19 vaccine development, showcasing the superiority of self-amplifying mRNA (sa-mRNA) technology over conventional mRNA vaccines. Key points include:

  • ARCT-154, an sa-mRNA vaccine, demonstrated superior immunogenicity and antibody persistence compared to Comirnaty® for up to 12 months post-vaccination.
  • Efficacy was achieved at one-sixth the dose (5 μg vs 30 μg) of the conventional mRNA vaccine.
  • The bivalent formula, ARCT-2301, showed superior immunogenicity over Comirnaty® that persisted against key variants up to 6 months post-vaccination.
  • At 12 months, ARCT-154 maintained a geometric mean titer ratio of 1.92 against the Wuhan-Hu-1 strain and 1.89 against Omicron BA.4-5.

These results suggest a potential paradigm shift in COVID-19 vaccine technology, offering longer-lasting protection with lower dosage requirements. This could have significant implications for vaccine production, distribution and global accessibility.

The study results have substantial implications for Arcturus Therapeutics (ARCT) and the broader vaccine market:

  • Market Potential: The superior performance of sa-mRNA technology could position ARCT as a leader in next-generation COVID-19 vaccines, potentially capturing significant market share.
  • Cost Efficiency: The lower dosage requirement (16.7% of conventional mRNA) could translate to reduced production costs and improved profit margins.
  • Competitive Advantage: The longer-lasting immune response addresses a key limitation of current vaccines, offering a distinct competitive edge.
  • Partnerships: The collaboration with CSL, a global biotechnology leader, enhances ARCT's credibility and market reach.
  • Future Applications: Success in COVID-19 vaccines could lead to applications of sa-mRNA technology in other areas, expanding ARCT's potential market.

Investors should monitor regulatory approvals, production scalability and market adoption rates as key indicators of ARCT's future performance.

Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL and Arcturus Therapeutics’ commitment to advancing COVID-19 vaccine innovation to protect public health.

WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)-- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and self-amplifying messenger RNA (sa-mRNA) pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a head-to-head study demonstrating that self-amplifying (sa-mRNA) COVID-19 vaccine maintained superior immunogenicity compared to the conventional mRNA vaccine Comirnaty® for up to one year against Wuhan-Hu-1, Omicron BA.4-5 and certain other variants, and at one-sixth the dose of the comparator (5 μg vs 30 μg, respectively).

The data, presented as a poster at the OPTIONS XII for the Control of Influenza conference, highlights 12-month follow-up analysis of the Phase 3 trial conducted in Japan by Meiji Seika Pharma, evaluating a booster dose of ARCT-154, showing that the vaccine elicited superior immunogenicity and antibody persistence over Comirnaty® for up to 12 months postvaccination, against multiple SARS-CoV-2 strains and in both younger and older adult age groups.

“The 12-month results from the ARCT-154 study continue to establish the durability of immune response from this self-amplifying mRNA vaccine and reinforce the ability of this vaccine to provide protection against COVID-19 at lower doses compared to conventional mRNA vaccines,” said Jonathan Edelman, M.D., Senior Vice President, Vaccines Innovation Unit, CSL. “We are proud to showcase at the 2024 OPTIONS conference with these important data about the first sa-mRNA COVID-19 vaccine now approved in Japan.”

Additional data presented by CSL and Arcturus finds that the bivalent formula, ARCT-2301, developed on the same platform as ARCT-154, induces superior immunogenicity over conventional bivalent mRNA vaccine Comirnaty® that persists against key variants up to six months postvaccination.

“The recent surge in COVID-19 infections and the emerging new variants illustrate the critical need for vaccines that provide a longer duration of protection compared to conventional mRNA vaccines,” said Igor Smolenov, M.D., Ph.D. Chief Development Officer of Arcturus Therapeutics. "These compelling new studies reaffirm that these sa-mRNA vaccines have the potential to offer potent protection against COVID-19.”

The COVID-19 vaccine from this sa-mRNA platform targeted against the JN.1 variant is approved in Japan for immunization against COVID-19 in adults 18 years and older and is being sold under the trade name KOSTAIVE®.

ARCT-154 12-month Study Design and Results

The randomized, double-blind, active-controlled Phase 3 study was conducted at 11 clinical sites in Japan. The study enrolled 828 adults who had previously been fully immunized with three doses of mRNA vaccine(s). Participants were randomized equally to receive a booster dose of either ARCT-154 or Comirnaty®. Immune responses were measured as neutralizing antibodies against the Wuhan-Hu-1 and Omicron BA.4-5 strains in sera obtained at Day 1 before booster vaccination, and Days 29, 91, 181, and 361 after vaccination of participants who were seronegative for SARS-CoV-2 nucleocapsid protein (N-protein), considered to be an indicator of recent COVID-19 infection. At the same timepoints neutralizing antibodies against Delta, Omicron BA.2, Omicron BA.2.86, and Omicron XBB.1.5.6 variants were measured in subsets of participants (~30 per group). Responses are expressed as group geometric mean titers (GMT) with 95% confidence intervals, and geometric mean titer ratio (GMTR) between the two vaccine groups at each timepoint.

At Day 29, neutralizing antibodies (GMTs unadjusted) against the Wuhan-Hu-1 strain in ARCT-154 recipients (n = 378) were superior to those in the Comirnaty® group (n = 374): GMT = 5390 (95% CI: 4899–5931) vs. 3738 (3442–4060), a GMT ratio of 1.44 (1.27–1.64). This advantage persisted through all time points. At Day 361 (unadjusted) GMTs were 3396 (3019–3821) and 1771 (1532–2047) in ARCT-154 (n = 272) and Comirnaty® (n = 266) groups, a GMT ratio of 1.92 (1.59–2.31). Differences were also observed in responses against Omicron BA.4-5, with GMT ratios of 1.31 (1.07–1.59) at Day 29 and 1.89 (1.42– 2.50) at Day 361. A subset of subjects who were seronegative for N-protein displayed similar differences in immune responses between ARCT-154 and Comirnaty® against the Delta, Omicron BA.2, BA.2.86, and XBB.1.5.6 variants at Day 361. The GMT ratios were 1.88 (0.79–4.49) against Delta, 2.34 (1.06–5.17) against Omicron BA.2, 2.51 (1.00–6.31) against Omicron BA.2.86 and 2.81 (1.09–7.28) against Omicron XBB.1.5.6.

Bivalent 6-month Study Design and Results

In this randomized, multicenter, Phase 3, observer-blind, active-controlled trial in Japan, fully-immunized (3‒5 doses of mRNA vaccine) adults were randomized 1:1 to receive a booster dose of ARCT-2301 or Comirnaty® Original/BA.4-5. The primary objective was to demonstrate non-inferiority of the immunogenicity of ARCT-2301 vs. Comirnaty® Original/BA.4-5 at Day 29 as neutralizing antibody GMT and seroresponse rates (SRR) against Omicron BA.4-5. Key secondary outcomes included titers of neutralizing antibodies against Wuhan-Hu-1 and Omicron XBB.1.5.

Between September and November 2023, 930 men and women (19‒80 years) with at least three prior mRNA COVID-19 vaccinations were enrolled at nine medical centers in Japan and administered ARCT-2301 (n = 465) or Comirnaty® Original/BA.4-5 (n = 465) boosters. At Day 29 ARCT-2301 (n = 398) induced superior neutralizing antibody responses vs. Comirnaty® (n = 405) against Omicron BA.4-5 (GMT ratio 1·49 [95% CI: 1.26–1.76], SRR difference 7.2% [95% CI: 0.6–13.7]), and against Wuhan-Hu-1 (GMT ratio 1.45 [1.28–1.63], SRR difference 12.5% [5.9–19.0]). The difference persisted through six months with GMT ratios of 2.17 (95% CI: 1.75-2.69) and 1.98 (95% CI: 1.69-2.31), respectively. Antibody responses against Omicron XBB.1.5 were also higher after ARCT-2301 vs. Comirnaty® (GMT ratio 1.63 [1.36–1.94], SRR difference 16.7% [10.1–23.2]).

About sa-mRNA

mRNA vaccines help protect against infectious diseases by providing a blueprint for cells in the body to make a protein to help our immune systems recognize and fight the disease. Unlike standard mRNA vaccines, self-amplifying mRNA vaccines instruct the body to make more mRNA and protein to boost the immune response.

About CSL

CSL (ASX:CSL; USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSLBehring.com/Vita and follow us on Twitter.com/CSL. For more information about CSL, visit www.CSL.com.

About Arcturus

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, are forward-looking statements, including those regarding strategy, future operations, the likelihood that KOSTAIVE will provide a longer duration of protection, the likelihood and timing of future approvals of KOSTAIVE anywhere in the world including Europe, the plans to submit additional regulatory filings and timing thereof, that preclinical or clinical data will be predictive of future clinical results, and the impact of general business and economic conditions. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements, including those discussed under the heading "Risk Factors" in Arcturus’ most recent Annual Report on Form 10-K, and in subsequent filings with, or submissions to, the SEC, which are available on the SEC’s website at www.sec.gov. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

CSL Media Contacts:

Sue Thorn

Mobile: 617 799 3151

Email: sue.thorn@cslbehring.com

Australia:

Jimmy Baker

Mobile: +61 450 909 211

Email: Jimmy.Baker@csl.com.au

Asia Pacific:

Hamish Walsh

+61 422 424 338

Email: hamish.walsh@seqirus.com

Arcturus Media Contact:

Neda Safarzadeh

VP, Head of IR/PR/Marketing

Email: IR@arcturusrx.com

Source: Arcturus Therapeutics Holdings Inc.

FAQ

What are the key findings of the ARCT-154 study compared to Comirnaty®?

The study showed ARCT-154 maintained superior immunogenicity compared to Comirnaty® for up to one year against multiple SARS-CoV-2 strains, including Wuhan-Hu-1 and Omicron variants, at one-sixth the dose (5 μg vs 30 μg).

How long did the ARCT-154 study last and what was its design?

The ARCT-154 study was a 12-month follow-up analysis of a Phase 3 trial conducted in Japan, evaluating a booster dose in 828 adults previously immunized with three doses of mRNA vaccine(s).

What were the results of the bivalent ARCT-2301 vaccine study?

The ARCT-2301 study showed superior immunogenicity over the conventional bivalent mRNA vaccine Comirnaty® that persisted against key variants up to six months post-vaccination.

Has any vaccine from Arcturus Therapeutics (ARCT) been approved for use?

Yes, the sa-mRNA platform vaccine targeting the JN.1 variant has been approved in Japan for immunization against COVID-19 in adults 18 years and older under the trade name KOSTAIVE®.

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

ARCT Rankings

ARCT Latest News

ARCT Stock Data

479.46M
27.04M
8.47%
93.19%
16.4%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO